The ROTOR platform will initially be developed and validated using rotavirus vaccine datasets.

INCHEON, South Korea, May 26, 2026 /PRNewswire/ -- SK bioscience announced that it has signed an agreement with Colombia's state-owned pharmaceutical company VECOL for vaccine technology transfer and ...

SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making. The project will support next-generation injectable ...

Novavax, Inc. (NASDAQ: NVAX), one of the leading Biotech stocks, and SK bioscience, Co. Limited expanded their collaboration and license agreements for NVX-CoV2373, Novavax's recombinant nanoparticle ...

SK Bioscience said Thursday it will lead a Gates Foundation-funded project to develop an AI-powered platform designed to ...

After striking out in the pandemic phase of COVID-19 with its belated vaccine, Novavax seeks to recover in the endemic phase. And a big part of the company's plan centers around enhancing its ...

First UNICEF procurement contract strengthens SK bioscience's presence in global public procurement markets Dual-hemisphere supply programs enhance manufacturing efficiency and operational ...

In South Korea, vaccine and biotech company SK bioscience will invest a total of $261 million — which includes a previous investment of $33 million — to establish the Songdo Global Research & Process ...

Company announces KRW3 billion donation to IVI to support advancement of global vaccine R&D November 17, 2022, SEOUL, Republic of Korea – SK bioscience, a leading vaccine manufacturer based in the ...

Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibody Technology licensed from Gates MRI; early studies confirm suppression of RSV infection ...

South Korean vaccine developer SK Bioscience Co Ltd is expected to raise 1.5 trillion won ($1.33 billion) in the country's largest IPO since 2017, after pricing the listing at the top of an indicative ...